Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAn open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
American Journal of Hematology, 09/01/09
Vij R et al. – Denosumab treatment of patients with relapsed or plateau-phase multiple myeloma achieved SD status within 3 mos.
Methods- Monthly doses of denosumab until ds progression
- Denosumab inhibited the RANKL pathway
- 21% of patients with relapsed myeloma achieved SD for 16.5 mos within 3 mos of tx
- 46% of patients with plateau-phase myeloma achieved SD for 18.3 mos within 3 mos of tx
Related Articles
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Relevance Score: 69%
Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09
Relevance Score: 69%
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 69%
A randomized phase III study on the effect of thalidomide combined with Adriamycin, dexamethasone (TAD), and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Blood, 11/23/09
Relevance Score: 67%
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Anticancer Research, 11/13/09
Relevance Score: 67%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/19/09
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Human Pathology, 12/19/09
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Leukemia and Lymphoma, 12/17/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
Leukemia and Lymphoma, 12/17/09
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Leukemia and Lymphoma, 12/17/09
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Leukemia and Lymphoma, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor